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Abstract Evidence suggests that amyloid-beta (Ab)
protein is a key factor in the pathogenesis of Alzheimer’s
disease (AD) and it has been recently proposed that mito-
chondria are involved in the biochemical pathway by
which Ab can lead to neuronal dysfunction. Here we
investigated the specific effects of Ab on mitochondrial
function under physiological conditions. Mitochondrial
respiratory functions and energy metabolism were ana-
lyzed in control and in human wild-type amyloid precursor
protein (APP) stably transfected human neuroblastoma
cells (SH-SY5Y). Mitochondrial respiratory capacity of
mitochondrial electron transport chain (ETC) in vital cells
was measured with a high-resolution respirometry system
(Oxygraph-2k). In addition, we determined the individual
activities of mitochondrial complexes I–IV that compose
ETC and ATP cellular levels. While the activities of
complexes I and II did not change between cell types,
complex IV activity was significantly reduced in APP cells.
In contrast, activity of complex III was significantly
enhanced in APP cells, as compensatory response in order
to balance the defect of complex IV. However, this com-
pensatory mechanism could not prevent the strong
impairment of total respiration in vital APP cells. As a
result, the respiratory control ratio (state3/state4) together
with ATP production decreased in the APP cells in com-
parison with the control cells. Chronic exposure to soluble
Ab protein may result in an impairment of energy
homeostasis due to a decreased respiratory capacity of
mitochondrial electron transport chain which, in turn, may
accelerate neurons demise.
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Introduction
Alzheimer’s disease (AD) is the most frequent form of
dementia among elderly individuals and is characterized by
neuropathological hallmarks of extracellular amyloid pla-
ques and intracellular neurofibrillary tangles in the brain of
AD patients. Extensive evidences suggest that amyloid-
beta (Ab) protein, which is derived from its precursor
protein APP, plays a pivotal role in the pathogenesis of
AD. In addition, mitochondrial dysfunction and energy
metabolism deficiencies have been recognized as earliest
events in AD (Chagnon et al. 1995) and have been corre-
lated with impairments of cognitive abilities in this clinical
scenario (Blass 2003). The most consistent defect of
mitochondrial electron transport chain enzymes in AD is
the deficiency in cytochrome c oxidase (complex IV)
activity in post-mortem brain tissues, as well as in other
tissues, such as platelets from AD patients and AD cybrid
cells (Cardoso et al. 2004a, b). Although, the specific
mechanisms leading to mitochondrial failure in AD still
remain unknown, a substantial body of evidence indicates
that Ab promotes neuronal degeneration and death by
enhancing neuron vulnerability to increase in levels of
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oxidative stress and impairments in cellular energy
metabolism (Gibson and Huang 2002; Mattson and Liu
2002). Interestingly, enzyme activities in mitochondrial
respiratory chain and citric acid cycle, which are reduced in
AD, can be inhibited by Ab in vitro. Furthermore, several
findings have demonstrated Ab-induced mitochondrial
damage, e.g., Ab inhibited cytochrome c oxidase (COX)
activity, in isolated brain mitochondria (Canevari et al.
1999; Parker et al. 1994). However, results on how mito-
chondrial respiratory chain complexes and complex IV are
affected by Ab are rather inconsistent (Casley et al. 2002b;
Cassarino and Bennett 1999; Swerdlow and Kish 2002). It
has been recently proposed that toxic species of Ab that
intervene in molecular and biochemical abnormalities in
AD may be intracellular oligomeric forms, instead of
extracellular, insoluble deposits. According to this
hypothesis, mitochondria could intervene in the mechanism
by which intracellular Ab triggers synaptic failure and
neurodegeneration (Eckert et al. 2008). This idea is sup-
ported by in vivo evidence of Ab accumulation within
mitochondria in brain tissues of AD patients (Fernandez-
Vizarra et al. 2004; Lustbader et al. 2004) and mitochon-
drial structural abnormalities (Hirai et al. 2001). Taken
together, these data indicate that mitochondrial dysfunction
can play a major role in AD pathophysiology (Eckert et al.
2003; Leuner et al. 2007; Rhein and Eckert 2007).
To unravel the direct impact of Ab on mitochondrial
respiratory functions, we established a new high resolution
respiratory protocol to investigate the respiratory capacity
of mitochondrial electron transport chain (ETC) under
physiological conditions in control and in wild-type APP
stably transfected human neuroblastoma cells (SH-SY5Y).
By means of stably transfected APP SH-SY5Y cells, which
represent a neuronal cell line of human origin widely used
in studies testing the effect of Ab in vitro, we circumvent
the artificial experimental design of most of the other
studies, where isolated mitochondria were treated with high
concentrations of Ab in the micromolar range (5–50 lM).
In addition, we determined the activities of mitochondrial




Stably expressing cell lines were obtained by transfecting
the human neuroblastoma SH-SY5Y with cDNAs (pCEP4
vector) containing either vector alone (control cells) or the
entire coding region of human APP (APP695) (Scheuer-
mann et al. 2001). Stably transfected cell clones were
selected with hygromycin (Scheuermann et al. 2001). Cells
were grown at 37C in DMEM medium supplemented with
10% calf serum, 2 mM L-glutamine, and 0.3 lg/ml
hygromycin.
Detection of Ab Levels
For the detection of secreted Ab1–40, we used a specific
sandwich enzyme-linked immunosorbent assay employing
monoclonal antibodies (Keil et al. 2004). The ELISA was
performed in accordance with the Abeta-ELISA kit by
Biosource. The assay principle is that of a standard sand-
wich ELISA, which utilizes a monoclonal mouse anti-
human Abeta1–16 capture antibody, a cleavage-site-specific
rabbit anti-human Abeta1–40 C-terminal detection antibody
and anti-rabbit IgG peroxidase-conjugated secondary
antibody.
Western Blot
Equal amounts (10–20 lg) of protein were loaded on a 4–
20% acryamide gel (Invitrogen, Germany) to perform
SDS-PAGE at 200 V for 50 min. The probes were trans-
ferred to a PVDF membrane (Amersham Biosciences,
Germany). Equal protein loading was confirmed by Pon-
ceau Red staining (Sigma, Germany). Membranes were
saturated with 5% nonfat dry milk for 1 h, washed three
times with TBST, and incubated with the primary antibody
(monoclonal anti-APP/Ab W02, Stratech, UK, or anti-
actin, Santa Cruz, Germany), overnight at 4C. After
washing with TBST, PVDF membranes were treated with
anti-IgG, horseradish-coupled secondary antibody (Cal-
biochem, Germany), for 1 h at room temperature. The
bands were specifically detected by enhanced chemilumi-
nescence reaction (ECL, Amersham, Germany).
Immunohistochemical Staining
Cells were plated at a density of 4 9 105 cells on collagen
treated coverslips. After 2 days growth, coverslips were
fixed in PBS with 4% PFA at 37 for 30 min, then per-
meabilized with 0.1% Triton for 15 min and blocked with
PBS 10% goat serum for 1 h at 37C. The coverslips were
incubated for 1 h at 37C with the primary antibody
(monoclonal mouse anti-APP MAB348, Chemicon Inter-
national, Switzerland, which recognizes amino acids 66–81
of the N-terminal of APP). After washing with PBS, they
were incubated for 30 min at 37C with the biotinylated
secondary antibody anti-mouse IgG (Sigma, Switzerland).
Then, they were incubated with Vectastain ABC reagent
(Vector Laboratories Inc., Burlingame) containing avidin
and horseradish peroxidase reagents for immunoperoxidase
staining. Finally, slides were incubated with AEC substrate
solution (Sigma, Switzerland) containing 3-amino-9-ethyl
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carbazole for localizing peroxidase in the cells by pro-
ducing a red reaction product. Staining was assessed using
a Zeiss Axiolab microscope. Black-and-white photographs
were taken.
Phase Contrast Microscopy and Morphological Anlysis
For the morphological analysis, cells were seeded at a
density of 4 9 104 cells/ml on coverslips previously coated
with 0.05 mg/ml collagen. Phase contrast pictures were
taken from living neuroblastoma cells using a Zeiss Axi-
olab microscope equipped with a digital camera Zeiss
AxioCam MRc.
Preparation of Isolated Mitochondria
Cells were incubated for 15 min in an ice-cold lysis buffer
[75 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4,
250 mM sucrose, 1 mM Pefabloc, 0.05% digitonine,
complete protease inhibitor mixture tablets (Roche
Diagnostics)]. Then, the cells were homogenized with a
glass homogenizer (10 strokes at 400 rpm and 5 strokes at
700 rpm), and the resulting homogenate was centrifuged at
8009g for 10 min at 4C to remove nuclei and tissue
particles. The supernatant 1 (S1) was saved and the pellet
was resuspended in the lysis buffer. The homogenization
step as well as the low-speed centrifugation step was
repeated. The supernatant 2 (S2) was saved and added to
the supernatant 1. The combined mitochondria-enriched
supernatants (S1 ? S2) were centrifuged at 20,0009g for
15 min at 4C to obtain the mitochondrial fraction. The
pellet was resuspended in PBS and stored at 4C until use,
followed by determination of protein content (Lowry et al.
1951).
Complex I Activity
A total of 300 lg of isolated mitochondria was solubilized
in n-dodecyl b-D-maltoside (20%). NADH:hexaamminer-
uthenium(III)-chloride (HAR) activity was measured at
30C in a buffer containing 2 mM Na?/MOPS, 50 mM
NaCl, and 2 mM KCN, pH 7.2, using 2 mM HAR and
200 lM NADH as substrates to estimate the complex I
content. To determine NADH-ubiquinone oxidoreductase
activity, 100 lM n-decylubiquinone (DBQ) and 100 lM
NADH were used as substrates and 5 lM rotenone as
inhibitor, as described previously (David et al. 2005; Dja-
farzadeh et al. 2000; Hauptmann et al. 2008). Oxidation
rates of NADH were recorded with a Shimadzu Multi
Spec-1501 diode array spectrophotometer (e340–400 nm =
6.1 mM-1 cm-1). Complex I activity was normalized to
the complex I content of the mitochondrial preparation and
is given as DBQ/HAR ratio.
Complex II Activity
The assay was performed by following the decrease in
absorbance at 600 nm, which results in the reduction of 2,6-
dichlorophenolindo-phenol (DCIP) in 1 ml of medium con-
taining 60 mM KH2PO4 (pH 7.4), 3 mM KCN, 20 lg/ml
rotenone, 20 mM succinate, and 20 lg mitochondrial pro-
tein. The reaction was initiated by the addition of 1.3 mM
phenazine methasulfate (PMS) and 0.18 mM DCIP as
described previously (Aleardi et al. 2005).The extinction
coefficient used for DCIP was 21 mM-1 cm-1.
Complex III Activity
The oxidation of 50 lM decylubiquinol obtained by com-
plex III was determined using cytochrome c as an electron
acceptor as described previously (Krahenbuhl et al. 1991).
Briefly, decylubiquinol is prepared by dissolving decyl-
ubiquinone (10 mM) in ethanol acidified to pH 2. The
quinone is reduced with excess solid sodium borohydride.
Decylubiquinol is extracted into diethylether:cyclohexane
(2:1, v/v) and evaporated to dryness under nitrogen gas,
dissolved in ethanol acidified to pH 2. The assay was
carried out in a medium containing 35 mM KH2PO4,
5 mM MgCl2, 2 mM KCN (pH 7.2), supplemented with
2.5 mg/ml BSA, 15 lM cytochrome c, 0,6 mM n-dodecyl
b-D-maltoside and 5 lg/ml rotenone. The reaction was
started with 10 lg of mitochondrial protein and the enzyme
activity was measured at 550 nm. The extinction coeffi-
cient used for cytochrome c was 18.5 mM-1 cm-1.
Complex IV Activity
Cytochrome c oxidase activity was determined in intact
isolated mitochondria (100 lg) using Cytochrome c oxi-
dase assay kit. The colorimetric assay is based on the
observation that a decrease in absorbance at 550 nm of
ferrocytochrome c is caused by its oxidation to ferricyto-
chrome c by cytochrome c oxidase. The cytochrome c
oxidase Assay was performed as described previously
(Rasmussen and Rasmussen 2000).
Mitochondrial Respiration in Vital Cells
Mitochondrial oxygen consumption was measured at 37C
using an Oroboros Oxygraph-2k system. Five millions of
cells were added to 2 ml of a mitochondrial respiration
medium containing 0.5 mM EGTA, 3 mM MgCl2, 60 mM
K-lactobionate, 20 mM Taurine, 10 mM KH2P04, 20 mM
HEPES, 110 mM Sucrose, 1 g/l BSA (pH 7.1). To measure
the state 4 (=state 2) of the complex I, 5 mM pyruvate and
2 mM malate were added and the cells were permeabilised
with 15 lg/ml digitonin. Afterward, 2 mM ADP is added
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to measure state 3 respiration, and, in order to increase the
respiratory capacity, 10 mM glutamate was added. To
study the effect of the convergent complex I ? II electron
input on the respiration, 10 mM of succinate was added.
The integrity of the mitochondrial membrane was checked
by the addition of 10 lM cytochrome c. After determining
coupled respiration, 0.4 lM FCCP (Carbonyl cyanide p-
(trifluoro-methoxy) phenyl-hydrazone) was added and
respiration was measured in the absence of a proton gra-
dient. In order to inhibit complex I and III activities,
0.5 lM rotenone and 2.5 lM antimycine A, respectively
were added. Mock and APP cells were measured in parallel
pairs using the same conditions (crossover design).
Citrate Synthase Activity
The reduction of 5,50-dithiobis(2-nitrobenzoic acid)
(DTNB) by citrate synthase at 412 nm (extinction coeffi-
cient of 13.6 mM-1 cm-1) was followed in a coupled
reaction with coenzyme A and oxaloacetate (Aleardi et al.
2005). Briefly, a reaction mixture of 0.2 M Tris–HCl,
pH 8.0, 0.1 mM acetyl-coenzymeA, 0.1 mM DTNB, n-
dodecyl-b-D-maltoside (20%) and 10 lg of mitochondrial
protein was incubated at 30C for 5 min. The reaction was
initiated by adding 0.5 mM oxaloacetate, and the absor-
bance change was monitored for 5 min with a Shimadzu
Multi-Spec-1501 diode array spectrophotometer.
Determination of ATP Levels
Cells were plated 1 day before at a density of 2.5 9 104
cells/well in a white 96-well plate. The kit is based on the
bioluminescent measurement of ATP. The bioluminescent
method utilizes the enzyme luciferase, which catalyzes the
formation of light from ATP and luciferin. The emitted
light was linearly related to the ATP concentration and was
measured using a luminometer (David et al. 2005; Keil
et al. 2004).
Statistical Analysis
Data are presented as mean ± S.E.M. For all statistical
comparison, Student’s t-test or Two-way ANOVA was used.
P values \ 0.05 were considered statistically significant.
Results
APP Expression and Ab Levels of APP Transfected
SH-SY5Y Cells
In our cell model, the overexpression of human wild-type
APP led to a significantly increased Aß secretion, as when
compared with control cells with the empty vector. The
APP expression of APPwt cells was substantially increased
in comparison with the control cells (Fig. 1b, d) confirming
previous findings (Scheuermann et al. 2001). The strong
expression of APP was not correlated with a change of the
general morphological aspect of APP cells when compared
with the control cells (Fig. 1a). APP cells secreted Ab
levels within pg/ml range, reflecting the physiological sit-
uation in vivo during cellular metabolism (Fig. 1c). Using
the APP SH-SY5Y cell line allows us to study effects of
chronic stress of soluble forms of Ab protein on cells and
mitochondria, respectively, as it may occur in the brains of
AD patients.
Amyloid-beta Leads to Mitochondrial Respiratory
Defects
To investigate mitochondrial capacity and function of
mitochondria in both control and APP cells, we initially
focused on the activity of the citrate synthase (CS) in both
cell types, which was similar in control and APP cells
(Fig. 2a). Given the direct inhibitory effect of extracellular
Ab on complex I (10% inhibition) (Aleardi et al. 2005), we
conducted direct measurements of the complex I activity.
NADH-ubiquinone oxidoreductase (NADH:DBQ) activity
in the mitochondrial APP cells did not alter, the same
occurring for NADH:HAR activity, indicating that the
complex I content was similar in both cell types. APP
mitochondria did not exhibit any loss in complex I activity,
as indicated by normalization of complex I activity with
complex I content expressed as DBQ/HAR ratio (Fig. 2b).
After normalization of complex I activity with the content
of mitochondria, complex I/CS ratio did not modify
between controls and APP cells (Fig. 2c). Moreover,
activity of respiratory chain complexes II, III and IV were
also normalized to the corresponding CS activity.
Accordingly, we found an unchanged complex II (Fig. 2d),
although there was a significantly up-regulated activity of
complex III in APP cells compared with control cells
(Fig. 2e). Similarly we observed a significantly reduced
cytochrome c oxidase activity between control and APP
mitochondria (Fig. 2f), which is consistent with the
reduced complex IV activity in platelets from AD patients
(Cardoso et al. 2004a), and the direct interaction of Ab
with mitochondrial membranes, which results in the inhi-
bition of complex IV in vivo (Canevari et al. 1999;
Hauptmann et al. 2008).
In order to evaluate the functionality of the respiratory
chain, we determined the physiological cell respiration in
vital control and APP cells (Fig. 3). We used the NADH
generating substrates, pyruvate and malate, to determine
state 4 of respiration (Fig. 3). State 3 respiration measures
the capacity of the mitochondria to metabolize oxygen and
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the selected substrate in the presence of a defined amount
of ADP, which is a substrate for the ATP synthase (com-
plex V). State 4 respiration represents a ‘‘basal-coupled’’
rate of respiratory chain activity and reflects activities of
respiratory chain complexes and proton leakage across the
inner mitochondrial membrane. We observed a signifi-
cantly reduced state 3 and state 4 respirations in the APP
cells (Fig. 3c). The addition of another substrate of com-
plex I, glutamate was not able to further increase cellular
respiration driven by complex I in both cell types. After-
ward, succinate was added as a substrate for complex II. In
control cells, addition of succinate substantially increases
total cell respiration, while in APP cells only a minor
increase was observed (Fig. 3a). In addition, after uncou-
pling with FCCP, the respiratory rate increased in the
absence of a proton gradient, which indicates the maximum
capacity of electron transport chain. This maximum
capacity was significantly enhanced in the control cells in
relation with the APP cells (Fig. 3a).
The respiratory control ratio (RCR) revealed a signifi-
cant effect of Ab on the coupling of mitochondrial
respiration, indicating that the relative efficiency of meta-
bolic coupling of electron chain complexes is impaired
under conditions of chronic stress evoked by soluble forms
of Ab in our APP cell model (Fig. 4a). ATP levels were
significantly reduced in APP cells (Fig. 4b). Taken toge-
ther, these results suggest that soluble species of Ab exhibit
an initial defect in mitochondrial function with reduced
complex IV activity that is translated into a mitochondrial
respiration deficiency with diminished ATP synthesis,
Fig. 1 Human APP and secreted Ab1–40 levels of SY5Y cells. a
Morphological analysis of native and transfected SH-SY5Y cells
showed neuroblast-like morphology with differentiated perikaria
(arrows) and occasional short neurites (arrowheads). Transfection
of SH-SY5Y cells with cDNAs (pCEP4 vector) containg the vector
alone or containing the entire coding region of human APP (APP695)
did not significantly change the general morphological aspect of the
cells. Scale bars 50 lm. b Human APP expression levels of SH-
SY5Y cells detected by western blotting using W02 antibody
indicating strong expression of APP in APP transfected cells
compared with control cells. c Cell culture supernatants of 5 9 106
SH-SY5Y cells (APPwt, Co) were collected and assayed for Ab1–40
by ELISA. Ab1–40 levels were significantly enhanced in APP cells
when compared with control cells (***P \ 0.001, n = 6, Student’s t-
test). d Human APP detected by immunochemistry using a mono-
clonal anti-APP antibody indicating stronger presence of APP in the
APP cells compared to the endogenous APP expression in control
cells
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which cannot be compensated by an increased activity of
complex III.
Discussion
A priori our findings support a toxic role of Ab in respi-
ration. Although the specific pathways that lead to energy
deprivation in AD remain unclear, there is evidence in
favor of Ab-induction of cell loss and synaptic failure by
energy deprivation and oxidative stress (Gibson and Huang
2002; Mattson and Liu 2002). Recently, the focus on toxic
species of Ab has switched from its extracellular and
fibrillar forms to its soluble species, e.g., oligomers, that
can be detected intracellularly and may represent the pri-
mary toxic Ab correlate (Fernandez-Vizarra et al. 2004;
Lustbader et al. 2004). Accoding to this novel hypothesis,
mitochondrial dysfunction may play a crucial role in the
biochemical pathway, by which Ab can lead to neuronal
dysfunction in AD (Eckert et al. 2008).
To unravel the effects of soluble species of Ab on the
mitochondrial respiratory capacity under physiological
conditions, we established for the first time, a high resolu-
tion respiratory protocol to perform whole cell recording of
total cellular respiration in control and with wild-type APP
stably transfected human neuroblastoma cells (SH-SY5Y).
We observed an impairment of oxygen consumption rate
and a decrease of respiratory control ratio (state3/state4) in
Fig. 2 Mitochondrial enzymes
activities in control and APP
cells. a Unaltered citrate
synthase activity between
control and APP cells. b
complex I activity (DBQ
activity) normalized to the
complex I content (HAR
activity) of the mitochondrial
preparation is shown as DBQ/
HAR ratio. Complex I activity
is unaltered. c unaltered
complex I/CS ratio. d unaltered
complex II/CS ratio. e complex
III/CS ratio was significantly
increased in the APP cells
(***, P \ 0.001 vs. control
cells, Student’s t-test). f
Complex IV/CS ratio was
significantly decreased in the
APP cells (**, P \ 0.01 vs.
control cells, Student’s t-test).
All values represent the
means ± S.E. from n = 4–6
independent experiments
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the APP that might be induced by the chronic over
expression of Ab within the low nanomolar range. This
defect of the whole mitochondrial respiratory chain may be
explained by the accumulated dysfunctions of one or sev-
eral mitochondrial chain complexes. To test this hypothesis,
we measured individual activities of mitochondrial com-
plexes I–IV as well as the ATP levels. Our results clearly
show a decrease in complex IV activity in the APP cells,
which is in accordance with the previous findings (Cardoso
et al. 2004a; Caspersen et al. 2005; Hauptmann et al. 2008).
Interestingly, the activity of the complex III significantly
increased, most probably as a compensatory mechanism in
response to the toxic effect of Ab on complex IV. Never-
theless, this compensatory response could not entirely
balance or avoid the impairment of cellular respiration. This
finding is in contrast to Caspersen et al. (2005). Accord-
ingly, a decrease of complex III activity was revealed,
together with a decrease of complex IV activity in brain
tissues from APP transgenic mice at the age of 12 months. It
is likely that in our cell model, we were able to detect a
premature intervention mechanism in response to soluble
forms of Ab as a compensatory increase of complex III
Fig. 3 High-resolution respirometry revealed a reduction of oxygen
consumption in APP cells. Representative diagrams of measurement
of oxygen (O2) consumption in control cells a and in APP cells b
demonstrating a decrease in the total O2 concentration with time. O2
flux and consumption by vital cells was measured after addition of
different agents: pyruvate/glutamate (pyr/glu), digitonin (dig), ADP,
glutamate (glu), succinate (suc), cytochrome c (cyt c), FCCP,
rotenone (rot), antimycine A (AA). c O2 consumption in control and
APP cells. Two-way ANOVA revealed a significant difference
between the cellular respiration of the two cell types (P \ 0.001). The
respiratory rates of mitochondria were significantly reduced in APP
cells. Values represent the means ± S.E. from n = 5 assays (cell
type)
Fig. 4 Reduced respiratory control ratio (state3/state4) (RCR) and
impaired ATP synthesis in APP cells. a Significantly reduced RCR in
APP cells (***, P \ 0.001 vs. control cells, Student’s t-test),
indicating an impaired efficiency of electron transport. Values
represent means ± S.E. from n = 5. b In accordance, ATP levels
are significantly reduced in APP cells (*, P \ 0.05 versus control
cells, Student’s t-test).Values represent means ± S.E. from n = 5
(measurements of control and APP cells were performed in parallel)
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activity, whereas the strong Ab load might have led to a
breakdown of that response thus decreasing complex III
activity. Moreover, we could show that complexes I and II
were not affected by Ab, which is in accordance with
findings on APP transgenic mice (Caspersen et al. 2005;
Hauptmann et al. 2008). However, it contrasts to in vitro
findings on isolated mitochondria, which were acutely
treated with rather high concentrations of aggregated and
fibrillar forms of Ab (5–50 lM), which in turn can induce
defects in nearly all complexes (Aleardi et al. 2005; Casley
et al. 2002a, b). Thus, nearly all other studies used synthetic
Ab peptides in the micromolar range, many orders of
magnitude over physiological levels, and cells or even
isolated mitochondria were exposed only to synthetic Ab
fragments. By contrast, our neuroblastoma cell model rep-
resents a very valuable approach to investigate AD-specific
cell death pathways by studying Ab levels within the pi-
comolar range. This cell model attempts to mimic
physiological conditions studying chronic effects of rather
low concentrations of Ab that are relevant for AD patients.
The fact that the mitochondrial dysfunction in our APP cell
model, especially the decrease in complex IV activity, is
already observed at picomolar concentrations and higher
amounts of synthetic Ab are needed to achieve a compa-
rable mitochondrial impairment also highlights the potential
role of other APP fragments, e.g., the carboxy-terminal APP
fragments (CTFs), which may accelerate the Ab-induced
mitochondrial failure (Jin et al. 2002; Chang and Suh 2005).
This is of special interest, since both, Ab and CTFs, can
accumulate intraneuronally. The neuronal loss and synaptic
transmission deficit in AD may therefore depend on in-
traneuronal accumulation of Ab and CTFs (Jin et al. 2002;
Chang and Suh 2005). Similarly, we showed that energy
production was impaired in the APP cells, which is cor-
roborated with other findings (Hauptmann et al. 2008; Keil
et al. 2004).
One can speculate that in humans, increased accumu-
lation and associated mitochondrial toxicity can be
underlying factors in the pathogenesis of AD. Initially, the
damaging effects of low physiological concentrations of
Ab may be partly compensated by an adaptive response,
e.g., increased complex III activity. However, when age-
related secondary stress occurs, pronounced mitochondrial
impairment might lead to the induction of cell death pro-
cesses, while in familial AD, high Ab load might be
directly responsible for mitochondrial and cellular dys-
function. In summary, we show novel and distinct actions
of Ab on mitochondria that may contribute to the patho-
genic outcome.
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